ArticleFrontiers in pharmacology2026
Efficacy of eltrombopag in combination with recombinant human thrombopoietin (rhTPO) for lymphoma patients with chemotherapy-induced thrombocytopenia.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To observe the efficacy and adverse reactions of eltrombopag combined with rhTPO in the treatment of lymphoma patients with chemotherapy - induced thrombocytopenia (CIT). Methods: A retrospective study was performed on the clinical data of 61 patients using eltrombopag (75 mg once a day), 99 patients using rhTPO (15,000 U once daily), and 50 patients using eltrombopag (75 mg once a day) combined with rhTPO (15,000 U once daily) in the treatment of lymphoma with CIT at the First Affiliated Hospital of Guangdong Pharmaceutical University from April 2017 to May 2022.66 patients with lymphoma after chemotherapy without any platelet-stimulating therapy were selected as observation controls. Administration of rhTPO and/or eltrombopag was initiated concurrently when the platelet count dropped below 50 × 10 Results: Pre-chemotherapy platelet count did not differ significantly among the three groups (eltrombopag, rhTPO, and combination), as indicated by P > 0.05. At day 5, mean platelet counts were (54.18 ± 20.63)×10 Conclusion: Eltrombopag combined with rhTPO is a effective and safe treatment for lymphoma with CIT, and the effect of the combination is better than that of eltrombopag or rhTPO alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.